Back to Search
Start Over
Improving outcomes for patients with relapsed multiple myeloma
- Source :
- Ramasamy, K, Gay, F, Weisel, K, Zweegman, S, Mateos, M V & Richardson, P 2021, ' Improving outcomes for patients with relapsed multiple myeloma : Challenges and considerations of current and emerging treatment options ', Blood Reviews, vol. 49, 100808 . https://doi.org/10.1016/j.blre.2021.100808
- Publication Year :
- 2021
-
Abstract
- Despite the recent introduction of new therapies for multiple myeloma (MM), it remains an incurable disease. As MM progresses, patients experience cycles of relapse and remission, with remission periods becoming increasingly shorter as the disease becomes less treatment-sensitive. The treatment of relapsed refractory MM (RRMM) remains a significant clinical challenge. Patients with RRMM are a highly heterogeneous group and choosing the most appropriate treatment requires careful consideration. Furthermore, the number of treatment options for MM is continually growing with no definitive consensus to guide treating clinicians. The emergence of second-generation proteasome inhibitors (e.g., carfilzomib and ixazomib), immunomodulatory drugs (e.g., pomalidomide) and monoclonal antibodies (e.g., isatuximab) has expanded an already complex treatment landscape. This review provides a clear summary of the available treatments for MM and discusses how to tailor treatments to individual patients' needs. Novel treatments currently under clinical development, including venetoclax, melflufen and CAR T-cell therapies, are also discussed.
- Subjects :
- medicine.medical_specialty
Antineoplastic Agents
Disease
Ixazomib
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Drug Discovery
medicine
Tailored
Treatment options
Humans
Intensive care medicine
Multiple myeloma
Isatuximab
business.industry
Venetoclax
Disease Management
Hematology
medicine.disease
Pomalidomide
Carfilzomib
Relapsed refractory
Treatment Outcome
Oncology
chemistry
Treatment landscape
030220 oncology & carcinogenesis
Novel agent
Neoplasm Recurrence, Local
Multiple Myeloma
business
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 0268960X
- Volume :
- 49
- Database :
- OpenAIRE
- Journal :
- Blood Reviews
- Accession number :
- edsair.doi.dedup.....74c574e06097e3ccd0474b7f4af17ef0